|
1) Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev. 1997; 155: 105-17
|
|
|
|
2) Lanier LL. NK cell receptors. Ann Rev Immunol. 1998; 16: 359
|
|
|
|
|
|
3) Phillips JH, Gumperz JE, Parham P, et al. Superantigen-dependent, cell-mediated cyto-toxicity inhibited by MHC class I receptors on T lymphocytes. Science. 1995; 268: 403-5
|
|
|
|
|
|
4) Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safe mechanism that may impair protective T-cell responses. Immunol Today. 1998; 19: 153-7
|
|
|
|
|
|
5) Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol. 2005; 35: 10-5
|
|
|
|
|
|
6) Ljunggren HG, Karre K. In search of the “missing self". MHC molecules and NK cell recognition. Immunol Today. 1990; 11: 237-44
|
|
|
|
|
|
7) Ruggeri L, Capanni M, Urbani E, et al. Effective-ness of donor natural liller cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097-100
|
|
|
|
|
|
8) Ruggeri L, Capanni M, Mancusi A, et al. Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Int J Hematol. 2005; 81: 13-7
|
|
|
|
|
9) Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110: 433-40
|
|
|
|
|
|
10) Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002; 100: 3825-7
|
|
|
|
|
|
11) Giebel S, Locatelli FW, Lamparelli T, et al. Surviv-al advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003; 31: 987-93
|
|
|
|
|
|
12) Hsu KC, Gooley T, Malkki M, et al. International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hemato-logic malignancy. Biol Blood Marrow Transplant. 2006; 12: 828-36
|
|
|
|
|
|
13) Farag SS, Bacigalupo A, Eapen M, et al. KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006; 12: 876-84
|
|
|
|
|
|
14) Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007; 109: 5058-61
|
|
|
|
|
|
15) 森島康雄, 編. In: GVHD予防・治療マニュアル. 東京: 南江堂; 2005
|
|
|
|
|
|
16) Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007; 13: 315-28
|
|
|
|
|
|
17) Yabe T, Matsuo K, Hirayasu K, et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2008; 14: 75-87
|
|
|
|
|
|
18) Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23: 492-500
|
|
|
|
|
|
19) Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009; 113: 5628-34
|
|
|
|
|
|
20) Yu J, Venstrom JM, Liu XR, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 3875-84
|
|
|
|
|
|
21) Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009; 113: 3119-29
|
|
|
|
|
|
22) Stringaris K, Adams S, Uribe M, et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant. 2010; 16: 1257-64
|
|
|
|
|
|
23) Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyelo-ablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010; 16: 533-42
|
|
|
|
|
|
24) Schönberg K, Sribar M, Enczmann J, et al. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood. 2011; 117: 98-107
|
|
|
|
|
|
25) Björklund AT, Schaffer M, Fauriat C, et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood. 2010; 115: 2686-94
|
|
|
|
|
|
26) Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010; 116: 2411-9
|
|
|
|
|
|
27) Kröger N, Zabelina T, Berger J, et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia. 2011 Jun 7 [Epub ahead of print]
|
|
|
|
|
|
28) Tanaka J, Mori A, Ohta S, et al. Expression of HLA-C specific natural killer cell receptor (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation. Br J Haematol. 2000; 108: 778-83
|
|
|
|
|
|
29) Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005; 106: 4370-6
|
|
|
|
|
|
30) Moretta L, Locatelli F, Pende D, et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011; 117: 764-71
|
|
|
|
|
|
31) Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105: 3051-7
|
|
|
|
|
|
32) Nguyen S, Béziat V, Norol F, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell trans-plantation. Transfusion. 2011 Feb18 [Epub ahead of print]
|
|
|
|
|
|
33) Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009; 69: 4010-7
|
|
|
|
|
|
34) Sola C, André P, Lemmers C, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009; 106: 12879-84
|
|
|
|
|
|
35) Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009; 114: 2667-77
|
|
|
|
|
|
36) Tanaka J, Sugita J, Shiratori S, et al. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia. (in press)
|
|
|
|
|